- Home
- ELVN vs IRS Comparison
ELVN vs IRS Comparison
Compare ELVN & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- IRS
- Stock Information
- Founded
- ELVN 2016
- IRS 1943
- Country
- ELVN United States
- IRS Argentina
- Employees
- ELVN N/A
- IRS N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- IRS Homebuilding
- Sector
- ELVN Health Care
- IRS Real Estate
- Exchange
- ELVN Nasdaq
- IRS Nasdaq
- Market Cap
- ELVN 1.0B
- IRS 1.1B
- IPO Year
- ELVN 2020
- IRS 1994
- Fundamental
- Price
- ELVN $21.60
- IRS $14.56
- Analyst Decision
- ELVN Strong Buy
- IRS Strong Buy
- Analyst Count
- ELVN 5
- IRS 1
- Target Price
- ELVN $37.80
- IRS $12.62
- AVG Volume (30 Days)
- ELVN 269.1K
- IRS 184.8K
- Earning Date
- ELVN 03-13-2025
- IRS 02-11-2025
- Dividend Yield
- ELVN N/A
- IRS 11.32%
- EPS Growth
- ELVN N/A
- IRS N/A
- EPS
- ELVN N/A
- IRS N/A
- Revenue
- ELVN N/A
- IRS $370,002,935.00
- Revenue This Year
- ELVN N/A
- IRS N/A
- Revenue Next Year
- ELVN N/A
- IRS N/A
- P/E Ratio
- ELVN N/A
- IRS N/A
- Revenue Growth
- ELVN N/A
- IRS N/A
- 52 Week Low
- ELVN $10.90
- IRS $7.32
- 52 Week High
- ELVN $30.03
- IRS $17.67
- Technical
- Relative Strength Index (RSI)
- ELVN 47.03
- IRS 41.44
- Support Level
- ELVN $20.40
- IRS $14.30
- Resistance Level
- ELVN $22.42
- IRS $15.70
- Average True Range (ATR)
- ELVN 1.25
- IRS 0.73
- MACD
- ELVN 0.06
- IRS -0.06
- Stochastic Oscillator
- ELVN 59.59
- IRS 12.57
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.